Key facts
- Kryptos Biotechnologies’s last known valuation is $48.5M (Feb 2025).
- It has raised $23.9M; the latest was Later Stage VC ($12.0M) in Feb 2025.
- Notable investors include University of California, Berkeley SkyDeck, FuturePlay, Mirae Asset Capital, KDB Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Kryptos Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Kryptos Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kryptos Biotechnologies
Developer of molecular diagnostic software designed for the diagnosis of infectious diseases. The company's platform develops a point-of-care, ultrafast photonic polymerase chain reaction that can create a fast photothermal heating plasmonic thin film by a light-emitting diode, enabling medical professionals to make the right clinical decision quickly at a reasonable cost.
- Sector
- Healthcare
- HQ
- Hayward, CA, United States
- Founded
- 2017
- Employees
- 8
- Website
- kryptosbio.com/
- Ownership
- Privately Held (backing)
Kryptos Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kryptos Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kryptos Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.